Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Multiple clinical trials of allogeneic T cell therapy use site-specific nucleases to disrupt T cell
receptor (TCR) and other genes,,,,–. In this study, using single-cell RNA sequencing, we …

Enhancing CRISPR-mediated site-specific transgene insertion efficiency by homology-
directed repair (HDR) using high concentrations of double-stranded DNA (dsDNA) with …

Immune cells are being engineered to recognize and respond to disease states, acting as a
“living drug” when transferred into patients. Therapies based on engineered immune cells …

The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …

The success of chimeric antigen receptor (CAR) T cells targeting B-cell malignancies
propelled the field of synthetic immunology and raised hopes to treat solid tumors in a …

Acute myeloid leukemia (AML) poses a singular challenge for chimeric antigen receptor
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …

The production of autologous T cells expressing a chimaeric antigen receptor (CAR) is time-
consuming, costly and occasionally unsuccessful. T-cell-derived induced pluripotent stem …

Advances in cell-based therapy, particularly CAR-T cell therapy, have transformed the
treatment of hematological malignancies. Although an important step forward for the field …